SCHEMBL2615554

SCHEMBL2615554

OCc1cccc(-c2ccccn2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.56
PRKCI P41743 1/20 0.56
FFAR1 O14842 1/20 0.51
FYN P06241 4/20 0.50
CBFB Q13951 1/20 0.49
KDM1A O60341 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
CDK8 P49336 1/20 0.47
CYP2A6 P11509 1/20 0.46
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSS P25774 1/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CCR1 P32246 1/20 0.45
CCR5 P51681 1/20 0.45
CCR8 P51685 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1139044 0.86 HRH3 (0.57) HRH3PRKCIFFAR1CDK8CYP2A6
SCHEMBL1733171 0.85 HRH3 (0.52) HRH3PRKCIFFAR1CYP2A6CTSL
SCHEMBL16595254 0.83 HRH3 (0.51) HRH3FFAR1CDK8CYP2A6CTSL
SCHEMBL4163504 0.82 HRH3 (0.56) HRH3FFAR1CYP2A6CTSLCTSB
SCHEMBL29793738 0.82 HRH3 (0.56) HRH3FFAR1CDK8CYP2A6KDM4E
SCHEMBL2696099 0.82 HRH3 (0.56) HRH3FFAR1CDK8CYP2A6KDM4E
SCHEMBL7392910 0.82 HRH3 (0.56) HRH3FFAR1CYP2A6CTSLCTSB
SCHEMBL3953179 0.82 HRH3 (0.56) HRH3FFAR1CYP2A6CTSLCTSB
SCHEMBL1129413 0.82 HRH3 (0.56) HRH3FFAR1CBFBCYP2A6CTSL
SCHEMBL13537177 0.82 HRH3 (0.56) HRH3FFAR1CYP2A6CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12442787-B2 Transition metal electron transfer complex having C—N ligand and electrochemical bio sensor using same I-SENS, INC. (KR) 2025-10-14 US disclosed
CN-114867732-B Novel transition metal electron transport complex having C-N ligand and electrochemical biosensor using the same 爱-森新株式会社 2024-11-29 CN disclosed
US-20230125122-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATION (KR) 2023-04-27 US disclosed
US-20230125122-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATION (KR) 2023-04-27 US disclosed
US-20230125122-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATION (KR) 2023-04-27 US disclosed
EP-4079740-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME I-SENS, INC. (KR) 2022-10-26 EP disclosed
EP-4079740-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME I-SENS, INC. (KR) 2022-10-26 EP disclosed
CN-114867732-A Novel transition metal electron transport complex having C-N ligand and electrochemical biosensor using the same 爱-森新株式会社 2022-08-05 CN disclosed
WO-2021125791-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME 주식회사 아이센스 2021-06-24 WO disclosed
WO-2021125791-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME 주식회사 아이센스 2021-06-24 WO disclosed
US-6989383-B1 Method of treating cancer SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2006-01-24 US disclosed
US-20050137207-A1 Method of treating cancer ROSEN NEAL (US) 2005-06-23 US disclosed
EP-0973396-A4 A METHOD OF TREATING CANCER MERCK & CO INC (US) 2001-02-07 EP disclosed
US-6060038-A Radiolabeled farnesyl-protein transferase inhibitors MERCK & CO., INC. (US) 2000-05-09 US disclosed
EP-0986302-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-03-22 EP disclosed
EP-0981728-A2 RADIOLABELED FARNESYL-PROTEIN TRANSFERASE INHIBITORS Merck & Co., Inc. (US) 2000-03-01 EP disclosed
EP-0973396-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-01-26 EP disclosed
WO-1999000654-A2 RADIOLABELED FARNESYL-PROTEIN TRANSFERASE INHIBITORS MERCK & CO., INC. (US) 1999-01-07 WO disclosed
WO-1998054966-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1998-12-10 WO disclosed
WO-1998044797-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125122-A1 NOVEL TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIO SENSOR USING SAME MB, CACYBP, SPR HRH3 4644/4885PRKCI 3155/4885FFAR1 4639/4885
US-12442787-B2 Transition metal electron transfer complex having C—N ligand and electrochemical bio sensor using same MB, CACYBP, SPR HRH3 4573/4885PRKCI 3100/4885FFAR1 4658/4885
US-20050137207-A1 Method of treating cancer FNTA, GGT1, NTPCR HRH3 4538/4885PRKCI 967/4885FFAR1 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.